Related Experiment Video

Updated: Nov 30, 2025

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.4K

Metabolic Response by 18F-FDG PET/CT in Metastatic Malignant Struma Ovarii Treated With Targeted Therapies

Romain-David Seban1, Laurence Bozec2, Camila Nascimento-Leite1

  • 1From the Departments of Nuclear Medicine and Endocrine Oncology.

Clinical Nuclear Medicine
|November 12, 2020
PubMed

Insights

Malignant struma ovarii (MSO) is a rare ovarian cancer. F-FDG PET/CT effectively assessed treatment response in a patient with metastatic MSO receiving targeted therapies.

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiology

Background:

  • Malignant struma ovarii (MSO) is a rare ovarian tumor mimicking differentiated thyroid cancer.
  • Lack of treatment guidelines and controversial role of imaging for response assessment in MSO.
  • Radioiodine-refractory metastatic MSO presents a therapeutic challenge.

Observation:

  • A 71-year-old woman with metastatic MSO was treated with targeted therapies.
  • First-line treatment involved lenvatinib, followed by pazopanib as second-line therapy.
  • The patient's condition was monitored using F-FDG PET/CT.

Findings:

  • F-FDG PET/CT demonstrated a metabolic response to targeted therapies.
  • Exceptional response observed in a patient with radioiodine-refractory MSO.
  • Successful therapeutic assessment of lenvatinib and pazopanib in MSO.

Implications:

  • F-FDG PET/CT is a valuable tool for assessing treatment response in MSO.
  • Highlights the utility of F-FDG PET/CT in managing rare cancers.
  • Supports the use of targeted therapies and advanced imaging in MSO management.

More Related Videos

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

11.2K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.3K

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
6.6K